THE CONFERENCE

The conference is about the key trends that will change the business in the coming years. Our specific major themes include:

 

CHARACTERISATION OF THE IMMUNE RESPONSE

 

IMMUNOTHERAPY AND PROFILING IN CANCER

  • The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis 
  • Analysis of the immune system during HIV infection
  • Optimized immune profiling by understanding T-cell and B-cell repertories during cancer
  • Next generation of immune checkpoint inhibitors.
  • Identifying solutions to improve the efficacy of PD-1 and CTLA-4 
  • Direct identification of neo-epitopes for cancer vaccines and adoptive T-Cell therapies
  • Next generation CAR Technology: Amplifying the immune response within the tumour microenvironment
  • Identifying immunogenic mutations to create immune diagnostics and effective immune monitoring of patients
  • Immunoscore®: An innovative combination of immunohistochemistry and digital pathology-based scoring
  • Oncolytic viruses: A new class of immunotherapy drugs
  • Next-generation biomarkers for the era of combination cancer immunotherapy

IMMUNOSEQUENCING AND HIGH THROUGHPUT ANALYSIS

BIOMARKERS AND SURROGATE MARKERS OF VACCINE EFFICACY AND SAFETY

  • Predictive & Precision medicine: Diagnostic testing, biomarkers and immunoassay systems
  • Rapidly screening a novel affinity scaffold library for PD-L1 Inhibitors
  • Immunosequencing: Combining high-throughput sequencing and bioinformatics to profile T-cell and B-cell receptors
  • Single-cell technologies: Validating discoveries and translating them into clinically useful diagnostic assays
  • Utilising next generation sequencing for fast and accurate processing of sequencing data from T- and B- cell receptor libraries
  • Developing novel antibody immunotherapies that help the immune system attack diseased cells
  • Signatures and ink spots of vaccine induced responses
  • Skin immunity for vaccination using omics to better describe the innate immunity and to predict the adaptive immunity
  • Systems integration of innate and adaptive immunity: Implications for vaccine development

 

 

WHO WILL ATTEND

 

Pharma and biotech 

 Law firms

Universities / Institutions 

 Private equity and venture capita

 

Key target job titles for the event include:

CEO/CSO/CMO – Biotech

 

Pharma and biotechs from:

  • Head of Immunology
  • Director Predictive Medicine
  • Director of Research
  • Directors of Biomarker Discovery & Diagnostics
  • Translational Science and Adjuvants
  • Head of Translational and Immuno-Oncology
  • Head of Sequencing / Next gen sequencing
  • Head of Cancer Immunotherapy
  • Head of Bioinformatics
  • Head of Vaccines